Chemomab changes CEOs, sus­pends mid-stage tri­al; Ex-FDA vac­cine of­fi­cial lends more help to Mesoblast

→ There’s a shake­up at the top of Chemomab Ther­a­peu­tics as the Is­raeli biotech halts the start of a Phase II study to save cash …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.